与随机第三期癌症临床试验的altmetric注意力得分相关的因素
Michael K Rooney1, Bahareh Sharifi1, Ethan B Ludmir1
1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
JCO clinical cancer informatics
|August 8, 2023
概括
癌症试验的Altmetric得分在FDA注册的治疗和尿生殖系统研究中更高. 这些得分与传统的文献计数如引用数量有很强的相关性.
科学领域:
- 在瘤学瘤学.
- 图书统计学 图书统计学
- 科学沟通科学沟通
背景情况:
- 另外,Altmetric注意力评分 (Altmetrics) 提供了实时的洞察力,可以超越传统的引用指标,更广泛地了解科学研究的影响.
- 了解影响临床试验中的Altmetrics因素可以帮助评估研究覆盖范围和参与度.
研究的目的:
- 在已发表的癌症临床试验中描述Altmetrics和传统文献计量之间的关系.
- 确定与更高的Altmetric注意力得分相关的癌症临床试验的特定特征.
主要方法:
- 2015-2020年间发表的第三期癌症随机临床试验的分析.
- 收集的数据包括Altmetrics,研究阳性,FDA注册状态,癌症部位,治疗背景和期刊层.
- 收集了参考资料 (引文,相对引文比率),并使用多重线性回归来识别Altmetrics的预测因素.
主要成果:
- 对98%的出版物获得了Altmetrics,平均得分为38.5.5.
- 美国食品和药物管理局的注册,治疗干预,生殖泌尿试验和Tier 1期刊出版物与更高的Altmetrics有显著的关联.
- 在Altmetrics和所有文献计量指标之间观察到强烈的相关性 (R2范围从0.63到0.67).
结论:
- 在FDA注册的癌症临床试验中,重点是治疗疗法,并且在生殖尿路类别中显示出最高的Altmetric参与度.
- 在Altmetrics和传统的文献计量指标之间存在着强大的关系.
- 需要进一步的研究来探索这些发现对科学影响评估的影响.
更多相关视频
07:50Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
265
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.5K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
01:12Hazard Ratio
158
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
158
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:16Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
01:21Cancer Survival Analysis
384
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
384
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K